MK-789 

MK-789 is a competitive reversible inhibitor of dehydropeptidase I (DHP-I). MK-789 competitively blocks the entry of N-formimidoylthienamycin into proximal tubular cells, thereby inhibiting its renal metabolism. MK-789 shifts the renal excretion pathway of N-formimidoylthienamycin to glomerular filtration only, increasing its urinary recovery rate and renal clearance. MK-789 is applicable to studies on renal metabolism and pharmacokinetics^[1].

MK-789 and its oxidative metabolites inhibit purified dehydropeptidase I in spectrophotometric assays.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MK-789 (25, 75, 150 mg; intravenous injection; single administration; 7-day washout period between each dose) increases the urinary recovery rate of co-administered 150 mg N-formimidoylthienamycin to a plateau value of approximately 61% in healthy Caucasian male subjects; it elevates the plasma AUC of co-administered N-formimidoylthienamycin by approximately 20% without altering its plasma half-life^[1].\n

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

253.34

C₁₄H₂₃NO₃

85394-14-5

O=C(/C(NC(C1CC1(C)C)=O)=C\CCCCC)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Norrby SR, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrobial agents and chemotherapy. 1983 Feb;23(2):300-7.  [Content Brief]